VERRICA PHARMACEUTICALS INC. - COMMON STOCK

0,6843

27-декабря-24 16:45:00

15 мин. задержка

Акции

+0,0356

+5,49%

Сегодняшний диапазон

0,6202 - 0,6918

ISIN

N/A

Источник

NASDAQ

Verrica Provides Business and Operational Update

20 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

09 дек 2024 16:15:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

06 дек 2024 08:00:00 Источник Nasdaq GlobeNewswire
Verrica Announces Pricing of $42.0 Million Public Offering

21 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verrica Announces Proposed Public Offering

20 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

04 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

24 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

02 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

04 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

14 авг 2024 07:45:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

14 авг 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

06 авг 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

01 июл 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

30 май 2024 16:30:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

15 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

13 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

09 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

08 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

02 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

26 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.